Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?

This study has been completed.
Information provided by (Responsible Party):
Maastricht University Medical Center Identifier:
First received: October 18, 2007
Last updated: June 10, 2014
Last verified: June 2014

Aim is to study if a paravertebral block as an adjunct to general anesthesia is a suitable technique for extended, one sided, breast surgery.

Condition Intervention Phase
Breast Cancer
Drug: standard anaesthesia (bupivacaine)
Drug: additional pvb (ropivacaine) and elastomeric disposable infusion pump
Drug: additional pvb (ropivacaine)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?

Resource links provided by NLM:

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • reduction of unplanned admissions and reduction of VAS score. [ Time Frame: one week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • to determine the safety and performance (efficacy) of the technique and the investigational product. [ Time Frame: one week ] [ Designated as safety issue: No ]

Enrollment: 46
Study Start Date: October 2006
Study Completion Date: May 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: standard anaesthesia (bupivacaine)
Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
Experimental: 2
PVB with ropivacaine and postoperative pump 5ml/h
Drug: additional pvb (ropivacaine) and elastomeric disposable infusion pump
Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
Experimental: Experimental 1
PVB with ropivacaine, 10 patients included but not analysed
Drug: additional pvb (ropivacaine)
Patients in group 1 will receive PVB with ropivacaine

Detailed Description:

Usually breast tumour surgery in the Academic Hospital Maastricht is performed under general anaesthesia. Perioperative pain management consists of paracetamol and naproxen preoperatively, opioids during surgery and local wound infiltration at the end of surgery with 10cc Bupivacaine 0.25%. Postoperative pain management consists of paracetamol, occasionally combined with Naproxen, and if necessary Piritramide 0.2 mg/kg i.m.

Alternatively there is the possibility to perform breast surgery under a thoracic paravertebral block (PVB) with or without general anesthesia.

A PVB according to Eason and Wyatt (1) can be performed preoperatively with insertion of an end-hole catheter T3-T4. With this technique we expect a better pain relief postoperatively.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Extended mamma surgery one-sided
  • ASA class I and II

Exclusion Criteria:

  • All contra indications for local anaesthesia
  • Coagulation disorders
  • Infection
  • Allergic reactions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00547989

University Hospital
Maastricht, Netherlands
Sponsors and Collaborators
Maastricht University Medical Center
Principal Investigator: Esther Bouman, MD azM
  More Information

No publications provided

Responsible Party: Maastricht University Medical Center Identifier: NCT00547989     History of Changes
Other Study ID Numbers: MEC 05-105.5
Study First Received: October 18, 2007
Last Updated: June 10, 2014
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
ASA class I and II

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Anesthetics, Local
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on February 25, 2015